ImmunoGen IncNASDAQ:IMGN
- LAST PRICE3.5400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.1500/ 10
- Ask / Lots3.6600/ 1
- Open / Previous Close0.0000 / 3.5400
- Day Range---
- 52 Week Range
- Volume22
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMGN |
|---|---|---|
| 09:32 ET | 57529 | 3.5 |
| 09:34 ET | 10271 | 3.48 |
| 09:36 ET | 11872 | 3.47 |
| 09:38 ET | 3081 | 3.46 |
| 09:39 ET | 4400 | 3.43 |
| 09:41 ET | 2391 | 3.435 |
| 09:43 ET | 11870 | 3.435 |
| 09:45 ET | 5307 | 3.42 |
| 09:48 ET | 3630 | 3.4 |
| 09:50 ET | 34110 | 3.41 |
| 09:52 ET | 143119 | 3.45 |
| 09:54 ET | 13363 | 3.435 |
| 09:56 ET | 3200 | 3.435 |
| 09:57 ET | 5885 | 3.445 |
| 09:59 ET | 3700 | 3.43 |
| 10:01 ET | 25082 | 3.42 |
| 10:03 ET | 8471 | 3.44 |
| 10:06 ET | 4724 | 3.44 |
| 10:08 ET | 13399 | 3.435 |
| 10:10 ET | 19685 | 3.42 |
| 10:12 ET | 10178 | 3.425 |
| 10:14 ET | 8176 | 3.445 |
| 10:15 ET | 16653 | 3.425 |
| 10:17 ET | 5312 | 3.445 |
| 10:19 ET | 51077 | 3.45 |
| 10:21 ET | 34401 | 3.48 |
| 10:24 ET | 20108 | 3.485 |
| 10:26 ET | 6068 | 3.49 |
| 10:28 ET | 45792 | 3.5 |
| 10:30 ET | 25104 | 3.5 |
| 10:32 ET | 11293 | 3.515 |
| 10:33 ET | 29794 | 3.52 |
| 10:35 ET | 15866 | 3.515 |
| 10:37 ET | 14049 | 3.525 |
| 10:39 ET | 25751 | 3.535 |
| 10:42 ET | 25892 | 3.5278 |
| 10:44 ET | 6787 | 3.54 |
| 10:46 ET | 10450 | 3.525 |
| 10:48 ET | 11737 | 3.535 |
| 10:50 ET | 18773 | 3.49 |
| 10:51 ET | 9914 | 3.495 |
| 10:53 ET | 17767 | 3.505 |
| 10:55 ET | 20248 | 3.51 |
| 10:57 ET | 8933 | 3.51 |
| 11:00 ET | 900 | 3.52 |
| 11:02 ET | 18054 | 3.51 |
| 11:04 ET | 5768 | 3.51 |
| 11:06 ET | 4009 | 3.51 |
| 11:08 ET | 2923 | 3.51 |
| 11:09 ET | 8986 | 3.53 |
| 11:11 ET | 2800 | 3.53 |
| 11:13 ET | 22484 | 3.5235 |
| 11:15 ET | 400 | 3.53 |
| 11:18 ET | 20514 | 3.53 |
| 11:20 ET | 19280 | 3.52 |
| 11:22 ET | 17170 | 3.52 |
| 11:24 ET | 12359 | 3.52 |
| 11:26 ET | 6613 | 3.535 |
| 11:27 ET | 500 | 3.54 |
| 11:29 ET | 5494 | 3.54 |
| 11:31 ET | 14097 | 3.545 |
| 11:33 ET | 1303 | 3.55 |
| 11:36 ET | 31130 | 3.54 |
| 11:38 ET | 1453 | 3.535 |
| 11:40 ET | 3000 | 3.545 |
| 11:42 ET | 12090 | 3.555 |
| 11:44 ET | 30419 | 3.555 |
| 11:45 ET | 14627 | 3.565 |
| 11:47 ET | 6652 | 3.57 |
| 11:49 ET | 10860 | 3.575 |
| 11:51 ET | 5783 | 3.57 |
| 11:54 ET | 5491 | 3.565 |
| 11:56 ET | 400 | 3.565 |
| 11:58 ET | 17356 | 3.57 |
| 12:00 ET | 4733 | 3.58 |
| 12:02 ET | 11305 | 3.575 |
| 12:03 ET | 10413 | 3.565 |
| 12:05 ET | 4322 | 3.57 |
| 12:07 ET | 9836 | 3.57 |
| 12:09 ET | 8458 | 3.58 |
| 12:12 ET | 4824 | 3.58 |
| 12:14 ET | 300 | 3.58 |
| 12:16 ET | 3884 | 3.59 |
| 12:18 ET | 10757 | 3.575 |
| 12:20 ET | 800 | 3.575 |
| 12:21 ET | 9817 | 3.575 |
| 12:23 ET | 7780 | 3.56 |
| 12:25 ET | 4208 | 3.565 |
| 12:27 ET | 17447 | 3.56 |
| 12:30 ET | 10601 | 3.55 |
| 12:32 ET | 58540 | 3.52 |
| 12:34 ET | 11720 | 3.52 |
| 12:36 ET | 7584 | 3.505 |
| 12:38 ET | 14861 | 3.51 |
| 12:39 ET | 8021 | 3.51 |
| 12:41 ET | 3985 | 3.52 |
| 12:43 ET | 4038 | 3.525 |
| 12:45 ET | 1100 | 3.53 |
| 12:48 ET | 1355 | 3.53 |
| 12:50 ET | 15324 | 3.52 |
| 12:52 ET | 3050 | 3.525 |
| 12:54 ET | 8726 | 3.525 |
| 12:56 ET | 1730 | 3.535 |
| 12:57 ET | 4906 | 3.54 |
| 12:59 ET | 28775 | 3.55 |
| 01:01 ET | 10063 | 3.53 |
| 01:03 ET | 13898 | 3.525 |
| 01:06 ET | 529 | 3.53 |
| 01:08 ET | 6306 | 3.53 |
| 01:10 ET | 9200 | 3.52 |
| 01:12 ET | 556 | 3.52 |
| 01:14 ET | 800 | 3.52 |
| 01:15 ET | 6787 | 3.505 |
| 01:17 ET | 4087 | 3.51 |
| 01:19 ET | 11968 | 3.505 |
| 01:21 ET | 8545 | 3.5 |
| 01:24 ET | 10809 | 3.505 |
| 01:26 ET | 4016 | 3.5 |
| 01:28 ET | 2300 | 3.505 |
| 01:30 ET | 5907 | 3.52 |
| 01:32 ET | 5118 | 3.52 |
| 01:33 ET | 4315 | 3.505 |
| 01:35 ET | 1718 | 3.52 |
| 01:37 ET | 800 | 3.52 |
| 01:39 ET | 3000 | 3.53 |
| 01:42 ET | 5586 | 3.54 |
| 01:44 ET | 28485 | 3.545 |
| 01:46 ET | 13985 | 3.55 |
| 01:48 ET | 7312 | 3.545 |
| 01:50 ET | 2800 | 3.55 |
| 01:51 ET | 16840 | 3.555 |
| 01:53 ET | 3700 | 3.56 |
| 01:55 ET | 11138 | 3.555 |
| 01:57 ET | 15856 | 3.545 |
| 02:00 ET | 800 | 3.545 |
| 02:02 ET | 4933 | 3.54 |
| 02:04 ET | 78356 | 3.545 |
| 02:06 ET | 1200 | 3.545 |
| 02:08 ET | 800 | 3.545 |
| 02:09 ET | 25140 | 3.56 |
| 02:11 ET | 2562 | 3.57 |
| 02:13 ET | 2500 | 3.565 |
| 02:15 ET | 22294 | 3.565 |
| 02:18 ET | 2100 | 3.565 |
| 02:20 ET | 5885 | 3.5544 |
| 02:22 ET | 11336 | 3.56 |
| 02:24 ET | 2529 | 3.565 |
| 02:26 ET | 3309 | 3.57 |
| 02:27 ET | 14616 | 3.575 |
| 02:29 ET | 3481 | 3.575 |
| 02:31 ET | 3226 | 3.575 |
| 02:33 ET | 2410 | 3.58 |
| 02:36 ET | 2558 | 3.58 |
| 02:38 ET | 15498 | 3.585 |
| 02:40 ET | 42461 | 3.595 |
| 02:42 ET | 36759 | 3.585 |
| 02:44 ET | 6683 | 3.575 |
| 02:45 ET | 18845 | 3.565 |
| 02:47 ET | 6841 | 3.555 |
| 02:49 ET | 18147 | 3.55 |
| 02:51 ET | 1548 | 3.545 |
| 02:54 ET | 1000 | 3.545 |
| 02:56 ET | 11022 | 3.535 |
| 02:58 ET | 14732 | 3.535 |
| 03:00 ET | 14350 | 3.53 |
| 03:02 ET | 9426 | 3.535 |
| 03:03 ET | 8900 | 3.535 |
| 03:05 ET | 5929 | 3.535 |
| 03:07 ET | 6544 | 3.53 |
| 03:09 ET | 6600 | 3.515 |
| 03:12 ET | 8819 | 3.525 |
| 03:14 ET | 6954 | 3.515 |
| 03:16 ET | 6174 | 3.515 |
| 03:18 ET | 3900 | 3.515 |
| 03:20 ET | 1500 | 3.515 |
| 03:21 ET | 25981 | 3.505 |
| 03:23 ET | 10444 | 3.515 |
| 03:25 ET | 1923 | 3.515 |
| 03:27 ET | 3957 | 3.515 |
| 03:30 ET | 19136 | 3.52 |
| 03:32 ET | 10858 | 3.52 |
| 03:34 ET | 5715 | 3.53 |
| 03:36 ET | 8077 | 3.54 |
| 03:38 ET | 6362 | 3.55 |
| 03:39 ET | 18198 | 3.565 |
| 03:41 ET | 24058 | 3.56 |
| 03:43 ET | 6949 | 3.56 |
| 03:45 ET | 28806 | 3.565 |
| 03:48 ET | 10750 | 3.55 |
| 03:50 ET | 32069 | 3.545 |
| 03:52 ET | 32166 | 3.55 |
| 03:54 ET | 39744 | 3.545 |
| 03:56 ET | 34672 | 3.54 |
| 03:57 ET | 61235 | 3.54 |
| 03:59 ET | 682584 | 3.54 |
May 23, 2022
Sector Update: Health Care Stocks Mixed Premarket Monday, from 9:14AM ET on Monday May 23, 2022 by MT Newswires
9:14AM ET on Monday May 23, 2022 by MT NewswiresThinking about buying stock in SIGA Technologies, Geovax Labs, Inovio Pharmaceuticals, ImmunoGen, or Emergent Biosolutions?, from 8:30AM ET on Monday May 23, 2022 by PR Newswire
8:30AM ET on Monday May 23, 2022 by PR NewswireBRIEF-Immunogen Announces Acceptance Of Biologics License Application For Mirvetuximab Soravtansine, from 7:45AM ET on Monday May 23, 2022 by Thomson Reuters
7:45AM ET on Monday May 23, 2022 by Thomson ReutersImmunoGen Says FDA Approves Biologics License Application of Mirvetuximab Soravtansine With Priority Review, from 6:42AM ET on Monday May 23, 2022 by MT Newswires
6:42AM ET on Monday May 23, 2022 by MT NewswiresImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review, from 6:30AM ET on Monday May 23, 2022 by Business Wire
6:30AM ET on Monday May 23, 2022 by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ImmunoGen Inc | 780.7M | -5.9x | --- |
Kymera Therapeutics Inc | 733.4M | -5.7x | --- |
Avid Bioservices Inc | 764.4M | 81.5x | --- |
Chinook Therapeutics Inc | 833.7M | -7.4x | --- |
Enanta Pharmaceuticals Inc | 812.6M | -7.1x | --- |
Deciphera Pharmaceuticals Inc | 712.5M | -2.2x | --- |
Company Information
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Mirvetuximab soravtansine is a first-in-class ADC targeting folate receptor alpha (FRα), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. IMGN632 (Pivekimab sunirine) is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. It is advancing pivekimab in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Contact Information
- Headquarters
- 830 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 781-895-0600
- Fax
- 781-895-0611
Executives
- Independent Chairman of the Board
- Stephen Mccluski
- President, Chief Executive Officer, Director
- Mark Enyedy
- Chief Financial Officer, Senior Vice President
- Susan Altschuller
- Senior Vice President, Chief Medical Officer
- Anna Berkenblit
- Senior Vice President, Chief Business Officer
- Stacy Coen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $780.7M |
|---|---|
Revenue (TTM) | $92.2M |
Shares Outstanding | 220.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-0.60 |
Book Value | $1.48 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 8.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -129.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
